Gilead Sciences sued over royalty payments on key HIV drug

67
3
Favorite

Gilead Sciences sued over royalty payments on key HIV drug

THE BUSINESS JOURNALS2021-12-28

HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

Michael721
·2021-12-28
Ok
Reply
2
Report
Roycethong
·2021-12-28
Yes yes
Reply
1
Report
WaiLoon_
·2021-12-28
👍🏻
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1151631589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-12-28 10:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151631589","market":"us","top_or_hot":-1,"title":"Gilead Sciences sued over royalty payments on key HIV drug","media":"THE BUSINESS JOURNALS","content":"<div>\n<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that ...</p>\n\n<a href=\"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo\">Source Link</a>\n\n</div>\n","source":"lsy1633760424806","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences sued over royalty payments on key HIV drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences sued over royalty payments on key HIV drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 10:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo><strong>THE BUSINESS JOURNALS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that ...</p>\n\n<a href=\"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RPRX","symbol_name":"Royalty Pharma plc","start_time":0,"source_url":"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo","article_id":"1151631589","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151631589","pubTimestamp":1640659721,"columns":[],"sourceInfo":{"source_id":"lsy1633760424806","name":"THE BUSINESS JOURNALS"},"weMediaInfo":null,"summary":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin ","collect":0,"end_time":0,"defaultTopTitle":"bizjournals.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RPRX":"Royalty Pharma plc","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","EXEL":"伊克力西斯","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"translate_title":"吉利德科学起诉支付关键艾滋病毒药物的版税","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":0.9,"GILD":0.9,"RPRX":0.9},"content_text":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that seeks $125 million in damages.\nIn the suit, filed Dec. 17 in San Mateo County Superior Court and moved last week to U.S. District Court in San Francisco, Royalty Pharma plc (NASDAQ: RPRX) claims Foster City-based Gilead (NASDAQ: GILD) failed to pay royalties on sales of drugs that use the antiviral therapy emtricitabine. That drug is sold as Emtriva but is now more often used as an ingredient in the HIV drugs Truvada, Atripla, Complera, Stribild, Eviplera, Genvoya, Odefsey, Descovy, Biktarvy and Symtuza.\nThe lawsuit was filed by Royalty Pharma Collection Trust, a Wilmington, Delaware-based unit of the New York company, the largest buyer of drug royalties.\nWith one-time cash payments to developers of drugs or technologies, companies such as Royalty Pharma provide capital in the present in exchange for a portion of a drug's sales in the future. The arrangement allows cash-strapped smaller companies or academic institutions, in particular, to monetize their work immediately instead of waiting for a drug to clear regulatory, sales or insurance reimbursement hurdles; for royalty buyers, it provides a potentially steady source of revenue for years to come.\nIn the case of emtricitabine, Gilead and Royalty Pharma in 2005agreed to pay $525 millionto Emory University to eliminate Emtriva royalties due to the Atlanta school. Gilead covered 65% of the payment with Royalty Pharma picking up the remainder.\nGilead also agreed to make a one-time payment of $15 million to Emory for amending its original license agreement with the university.\nBut in a heavily redacted copy of the suit — 6-1/2 pages of the 12-page document, including the bulk of Royalty Pharma's claims, are blacked out — Royalty Pharma said Gilead has breached the agreement by failing to make royalty payouts as they were due.\nRoyalty Pharma seeks recovery of what it claims is $125 million in damages, plus interest, attorneys' fees and costs and any other award from the court, and a declaration that Gilead must continue to pay royalties.\nIn a statement to the San Francisco Business Times, Gilead said it is aware of the lawsuit and \"believes Royalty Pharma's claims are without merit and (Gilead) intends to vigorously defend itself against them.\"\nEmtriva was discovered by Emory researchers Dr.Dennis Liotta, Dr.Raymond Schinaziand Dr.Woo-Baeg Choiand licensed in 1996 to Triangle Pharmaceuticals by Emory. Triangle was bought by Gilead in January 2003 and Emtriva was approved by the Food and Drug Administration six months later.\nEmtricitabine, which acts with other drugs to slow the progress of the AIDS virus, has gone on to become a keystone in multiple HIV drugs developed and marketed by Gilead. That portfolio includes the once-daily, two-drug combo Truvada, which is approved as an HIV treatment but also was the first drug greenlighted to prevent HIV infection, and Symtuza, a drug approved in 2018 for Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit.\nHIV drug sales remain Gilead's top category, accounting for nearly $11.8 billion of the company's $19.8 billion in revenue in the nine months of this year ended Sept. 30.\nGilead registered a profit of $5.8 billion through the first three quarters.\nDespite Gilead's successful expansion into hepatitis C, hepatitis B, cancer and cell therapy, those drugs either delivered a short pop in revenue or are too early in their product lifecycles to account for much revenue compared to the company's HIV franchise. The current exception is the Covid-19 drug remdesivir, branded as Veklury, that had 2021 sales through the third quarter of $4.2 billion.\nRoyalty Pharma has had several agreements involving Bay Area drug makers, including royalties on the cancer drugs Cabometyx and Cometriq that were developed by Alameda's Exelixis Inc. (NASDAQ: EXEL) and Novato-based Ultragenyx Pharmaceuticals Inc.'s (NASDAQ: RARE) rare disease drug Crysvita.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9009642308,"gmtCreate":1640662296645,"gmtModify":1676533532704,"author":{"id":"3585263840511239","authorId":"3585263840511239","name":"Michael721","avatar":"https://static.tigerbbs.com/91de9715c201776b7b2355a8ed218573","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585263840511239","authorIdStr":"3585263840511239"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009642308","repostId":1151631589,"repostType":4,"repost":{"id":"1151631589","kind":"news","pubTimestamp":1640659721,"share":"https://ttm.financial/m/news/1151631589?lang=&edition=fundamental","pubTime":"2021-12-28 10:48","market":"us","language":"en","title":"Gilead Sciences sued over royalty payments on key HIV drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1151631589","media":"THE BUSINESS JOURNALS","summary":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin ","content":"<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that seeks $125 million in damages.</p>\n<p>In the suit, filed Dec. 17 in San Mateo County Superior Court and moved last week to U.S. District Court in San Francisco, <a href=\"https://laohu8.com/S/RPRX\">Royalty Pharma plc</a> (NASDAQ: RPRX) claims Foster City-based Gilead (NASDAQ: GILD) failed to pay royalties on sales of drugs that use the antiviral therapy emtricitabine. That drug is sold as Emtriva but is now more often used as an ingredient in the HIV drugs Truvada, Atripla, Complera, Stribild, Eviplera, Genvoya, Odefsey, Descovy, Biktarvy and Symtuza.</p>\n<p>The lawsuit was filed by Royalty Pharma Collection Trust, a Wilmington, Delaware-based unit of the New York company, the largest buyer of drug royalties.</p>\n<p>With <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time cash payments to developers of drugs or technologies, companies such as Royalty Pharma provide capital in the present in exchange for a portion of a drug's sales in the future. The arrangement allows cash-strapped smaller companies or academic institutions, in particular, to monetize their work immediately instead of waiting for a drug to clear regulatory, sales or insurance reimbursement hurdles; for royalty buyers, it provides a potentially steady source of revenue for years to come.</p>\n<p>In the case of emtricitabine, Gilead and Royalty Pharma in 2005agreed to pay $525 millionto Emory University to eliminate Emtriva royalties due to the Atlanta school. Gilead covered 65% of the payment with Royalty Pharma picking up the remainder.</p>\n<p>Gilead also agreed to make a one-time payment of $15 million to Emory for amending its original license agreement with the university.</p>\n<p>But in a heavily redacted copy of the suit — 6-1/2 pages of the 12-page document, including the bulk of Royalty Pharma's claims, are blacked out — Royalty Pharma said Gilead has breached the agreement by failing to make royalty payouts as they were due.</p>\n<p>Royalty Pharma seeks recovery of what it claims is $125 million in damages, plus interest, attorneys' fees and costs and any other award from the court, and a declaration that Gilead must continue to pay royalties.</p>\n<p>In a statement to the San Francisco Business Times, Gilead said it is aware of the lawsuit and \"believes Royalty Pharma's claims are without merit and (Gilead) intends to vigorously defend itself against them.\"</p>\n<p>Emtriva was discovered by Emory researchers Dr.Dennis Liotta, Dr.Raymond Schinaziand Dr.Woo-Baeg Choiand licensed in 1996 to Triangle Pharmaceuticals by Emory. Triangle was bought by Gilead in January 2003 and Emtriva was approved by the Food and Drug Administration six months later.</p>\n<p>Emtricitabine, which acts with other drugs to slow the progress of the AIDS virus, has gone on to become a keystone in multiple HIV drugs developed and marketed by Gilead. That portfolio includes the once-daily, two-drug combo Truvada, which is approved as an HIV treatment but also was the first drug greenlighted to prevent HIV infection, and Symtuza, a drug approved in 2018 for Johnson &amp; Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit.</p>\n<p>HIV drug sales remain Gilead's top category, accounting for nearly $11.8 billion of the company's $19.8 billion in revenue in the nine months of this year ended Sept. 30.</p>\n<p>Gilead registered a profit of $5.8 billion through the first three quarters.</p>\n<p>Despite Gilead's successful expansion into hepatitis C, hepatitis B, cancer and cell therapy, those drugs either delivered a short pop in revenue or are too early in their product lifecycles to account for much revenue compared to the company's HIV franchise. The current exception is the Covid-19 drug remdesivir, branded as Veklury, that had 2021 sales through the third quarter of $4.2 billion.</p>\n<p>Royalty Pharma has had several agreements involving Bay Area drug makers, including royalties on the cancer drugs Cabometyx and Cometriq that were developed by Alameda's Exelixis Inc. (NASDAQ: EXEL) and Novato-based Ultragenyx Pharmaceuticals Inc.'s (NASDAQ: RARE) rare disease drug Crysvita.</p>","source":"lsy1633760424806","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences sued over royalty payments on key HIV drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences sued over royalty payments on key HIV drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 10:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo><strong>THE BUSINESS JOURNALS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that ...</p>\n\n<a href=\"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","GILD":"吉利德科学","BK4550":"红杉资本持仓","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","EXEL":"伊克力西斯","RPRX":"Royalty Pharma plc","BK4139":"生物科技"},"source_url":"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151631589","content_text":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that seeks $125 million in damages.\nIn the suit, filed Dec. 17 in San Mateo County Superior Court and moved last week to U.S. District Court in San Francisco, Royalty Pharma plc (NASDAQ: RPRX) claims Foster City-based Gilead (NASDAQ: GILD) failed to pay royalties on sales of drugs that use the antiviral therapy emtricitabine. That drug is sold as Emtriva but is now more often used as an ingredient in the HIV drugs Truvada, Atripla, Complera, Stribild, Eviplera, Genvoya, Odefsey, Descovy, Biktarvy and Symtuza.\nThe lawsuit was filed by Royalty Pharma Collection Trust, a Wilmington, Delaware-based unit of the New York company, the largest buyer of drug royalties.\nWith one-time cash payments to developers of drugs or technologies, companies such as Royalty Pharma provide capital in the present in exchange for a portion of a drug's sales in the future. The arrangement allows cash-strapped smaller companies or academic institutions, in particular, to monetize their work immediately instead of waiting for a drug to clear regulatory, sales or insurance reimbursement hurdles; for royalty buyers, it provides a potentially steady source of revenue for years to come.\nIn the case of emtricitabine, Gilead and Royalty Pharma in 2005agreed to pay $525 millionto Emory University to eliminate Emtriva royalties due to the Atlanta school. Gilead covered 65% of the payment with Royalty Pharma picking up the remainder.\nGilead also agreed to make a one-time payment of $15 million to Emory for amending its original license agreement with the university.\nBut in a heavily redacted copy of the suit — 6-1/2 pages of the 12-page document, including the bulk of Royalty Pharma's claims, are blacked out — Royalty Pharma said Gilead has breached the agreement by failing to make royalty payouts as they were due.\nRoyalty Pharma seeks recovery of what it claims is $125 million in damages, plus interest, attorneys' fees and costs and any other award from the court, and a declaration that Gilead must continue to pay royalties.\nIn a statement to the San Francisco Business Times, Gilead said it is aware of the lawsuit and \"believes Royalty Pharma's claims are without merit and (Gilead) intends to vigorously defend itself against them.\"\nEmtriva was discovered by Emory researchers Dr.Dennis Liotta, Dr.Raymond Schinaziand Dr.Woo-Baeg Choiand licensed in 1996 to Triangle Pharmaceuticals by Emory. Triangle was bought by Gilead in January 2003 and Emtriva was approved by the Food and Drug Administration six months later.\nEmtricitabine, which acts with other drugs to slow the progress of the AIDS virus, has gone on to become a keystone in multiple HIV drugs developed and marketed by Gilead. That portfolio includes the once-daily, two-drug combo Truvada, which is approved as an HIV treatment but also was the first drug greenlighted to prevent HIV infection, and Symtuza, a drug approved in 2018 for Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit.\nHIV drug sales remain Gilead's top category, accounting for nearly $11.8 billion of the company's $19.8 billion in revenue in the nine months of this year ended Sept. 30.\nGilead registered a profit of $5.8 billion through the first three quarters.\nDespite Gilead's successful expansion into hepatitis C, hepatitis B, cancer and cell therapy, those drugs either delivered a short pop in revenue or are too early in their product lifecycles to account for much revenue compared to the company's HIV franchise. The current exception is the Covid-19 drug remdesivir, branded as Veklury, that had 2021 sales through the third quarter of $4.2 billion.\nRoyalty Pharma has had several agreements involving Bay Area drug makers, including royalties on the cancer drugs Cabometyx and Cometriq that were developed by Alameda's Exelixis Inc. (NASDAQ: EXEL) and Novato-based Ultragenyx Pharmaceuticals Inc.'s (NASDAQ: RARE) rare disease drug Crysvita.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9009646964,"gmtCreate":1640661808249,"gmtModify":1676533532680,"author":{"id":"3576226408916865","authorId":"3576226408916865","name":"Roycethong","avatar":"https://static.tigerbbs.com/3a4f83d55f675e37e2b2e725f614ebf5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576226408916865","authorIdStr":"3576226408916865"},"htmlText":"Yes yes","listText":"Yes yes","text":"Yes yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009646964","repostId":1151631589,"repostType":4,"repost":{"id":"1151631589","kind":"news","pubTimestamp":1640659721,"share":"https://ttm.financial/m/news/1151631589?lang=&edition=fundamental","pubTime":"2021-12-28 10:48","market":"us","language":"en","title":"Gilead Sciences sued over royalty payments on key HIV drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1151631589","media":"THE BUSINESS JOURNALS","summary":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin ","content":"<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that seeks $125 million in damages.</p>\n<p>In the suit, filed Dec. 17 in San Mateo County Superior Court and moved last week to U.S. District Court in San Francisco, <a href=\"https://laohu8.com/S/RPRX\">Royalty Pharma plc</a> (NASDAQ: RPRX) claims Foster City-based Gilead (NASDAQ: GILD) failed to pay royalties on sales of drugs that use the antiviral therapy emtricitabine. That drug is sold as Emtriva but is now more often used as an ingredient in the HIV drugs Truvada, Atripla, Complera, Stribild, Eviplera, Genvoya, Odefsey, Descovy, Biktarvy and Symtuza.</p>\n<p>The lawsuit was filed by Royalty Pharma Collection Trust, a Wilmington, Delaware-based unit of the New York company, the largest buyer of drug royalties.</p>\n<p>With <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time cash payments to developers of drugs or technologies, companies such as Royalty Pharma provide capital in the present in exchange for a portion of a drug's sales in the future. The arrangement allows cash-strapped smaller companies or academic institutions, in particular, to monetize their work immediately instead of waiting for a drug to clear regulatory, sales or insurance reimbursement hurdles; for royalty buyers, it provides a potentially steady source of revenue for years to come.</p>\n<p>In the case of emtricitabine, Gilead and Royalty Pharma in 2005agreed to pay $525 millionto Emory University to eliminate Emtriva royalties due to the Atlanta school. Gilead covered 65% of the payment with Royalty Pharma picking up the remainder.</p>\n<p>Gilead also agreed to make a one-time payment of $15 million to Emory for amending its original license agreement with the university.</p>\n<p>But in a heavily redacted copy of the suit — 6-1/2 pages of the 12-page document, including the bulk of Royalty Pharma's claims, are blacked out — Royalty Pharma said Gilead has breached the agreement by failing to make royalty payouts as they were due.</p>\n<p>Royalty Pharma seeks recovery of what it claims is $125 million in damages, plus interest, attorneys' fees and costs and any other award from the court, and a declaration that Gilead must continue to pay royalties.</p>\n<p>In a statement to the San Francisco Business Times, Gilead said it is aware of the lawsuit and \"believes Royalty Pharma's claims are without merit and (Gilead) intends to vigorously defend itself against them.\"</p>\n<p>Emtriva was discovered by Emory researchers Dr.Dennis Liotta, Dr.Raymond Schinaziand Dr.Woo-Baeg Choiand licensed in 1996 to Triangle Pharmaceuticals by Emory. Triangle was bought by Gilead in January 2003 and Emtriva was approved by the Food and Drug Administration six months later.</p>\n<p>Emtricitabine, which acts with other drugs to slow the progress of the AIDS virus, has gone on to become a keystone in multiple HIV drugs developed and marketed by Gilead. That portfolio includes the once-daily, two-drug combo Truvada, which is approved as an HIV treatment but also was the first drug greenlighted to prevent HIV infection, and Symtuza, a drug approved in 2018 for Johnson &amp; Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit.</p>\n<p>HIV drug sales remain Gilead's top category, accounting for nearly $11.8 billion of the company's $19.8 billion in revenue in the nine months of this year ended Sept. 30.</p>\n<p>Gilead registered a profit of $5.8 billion through the first three quarters.</p>\n<p>Despite Gilead's successful expansion into hepatitis C, hepatitis B, cancer and cell therapy, those drugs either delivered a short pop in revenue or are too early in their product lifecycles to account for much revenue compared to the company's HIV franchise. The current exception is the Covid-19 drug remdesivir, branded as Veklury, that had 2021 sales through the third quarter of $4.2 billion.</p>\n<p>Royalty Pharma has had several agreements involving Bay Area drug makers, including royalties on the cancer drugs Cabometyx and Cometriq that were developed by Alameda's Exelixis Inc. (NASDAQ: EXEL) and Novato-based Ultragenyx Pharmaceuticals Inc.'s (NASDAQ: RARE) rare disease drug Crysvita.</p>","source":"lsy1633760424806","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences sued over royalty payments on key HIV drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences sued over royalty payments on key HIV drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 10:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo><strong>THE BUSINESS JOURNALS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that ...</p>\n\n<a href=\"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","GILD":"吉利德科学","BK4550":"红杉资本持仓","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","EXEL":"伊克力西斯","RPRX":"Royalty Pharma plc","BK4139":"生物科技"},"source_url":"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151631589","content_text":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that seeks $125 million in damages.\nIn the suit, filed Dec. 17 in San Mateo County Superior Court and moved last week to U.S. District Court in San Francisco, Royalty Pharma plc (NASDAQ: RPRX) claims Foster City-based Gilead (NASDAQ: GILD) failed to pay royalties on sales of drugs that use the antiviral therapy emtricitabine. That drug is sold as Emtriva but is now more often used as an ingredient in the HIV drugs Truvada, Atripla, Complera, Stribild, Eviplera, Genvoya, Odefsey, Descovy, Biktarvy and Symtuza.\nThe lawsuit was filed by Royalty Pharma Collection Trust, a Wilmington, Delaware-based unit of the New York company, the largest buyer of drug royalties.\nWith one-time cash payments to developers of drugs or technologies, companies such as Royalty Pharma provide capital in the present in exchange for a portion of a drug's sales in the future. The arrangement allows cash-strapped smaller companies or academic institutions, in particular, to monetize their work immediately instead of waiting for a drug to clear regulatory, sales or insurance reimbursement hurdles; for royalty buyers, it provides a potentially steady source of revenue for years to come.\nIn the case of emtricitabine, Gilead and Royalty Pharma in 2005agreed to pay $525 millionto Emory University to eliminate Emtriva royalties due to the Atlanta school. Gilead covered 65% of the payment with Royalty Pharma picking up the remainder.\nGilead also agreed to make a one-time payment of $15 million to Emory for amending its original license agreement with the university.\nBut in a heavily redacted copy of the suit — 6-1/2 pages of the 12-page document, including the bulk of Royalty Pharma's claims, are blacked out — Royalty Pharma said Gilead has breached the agreement by failing to make royalty payouts as they were due.\nRoyalty Pharma seeks recovery of what it claims is $125 million in damages, plus interest, attorneys' fees and costs and any other award from the court, and a declaration that Gilead must continue to pay royalties.\nIn a statement to the San Francisco Business Times, Gilead said it is aware of the lawsuit and \"believes Royalty Pharma's claims are without merit and (Gilead) intends to vigorously defend itself against them.\"\nEmtriva was discovered by Emory researchers Dr.Dennis Liotta, Dr.Raymond Schinaziand Dr.Woo-Baeg Choiand licensed in 1996 to Triangle Pharmaceuticals by Emory. Triangle was bought by Gilead in January 2003 and Emtriva was approved by the Food and Drug Administration six months later.\nEmtricitabine, which acts with other drugs to slow the progress of the AIDS virus, has gone on to become a keystone in multiple HIV drugs developed and marketed by Gilead. That portfolio includes the once-daily, two-drug combo Truvada, which is approved as an HIV treatment but also was the first drug greenlighted to prevent HIV infection, and Symtuza, a drug approved in 2018 for Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit.\nHIV drug sales remain Gilead's top category, accounting for nearly $11.8 billion of the company's $19.8 billion in revenue in the nine months of this year ended Sept. 30.\nGilead registered a profit of $5.8 billion through the first three quarters.\nDespite Gilead's successful expansion into hepatitis C, hepatitis B, cancer and cell therapy, those drugs either delivered a short pop in revenue or are too early in their product lifecycles to account for much revenue compared to the company's HIV franchise. The current exception is the Covid-19 drug remdesivir, branded as Veklury, that had 2021 sales through the third quarter of $4.2 billion.\nRoyalty Pharma has had several agreements involving Bay Area drug makers, including royalties on the cancer drugs Cabometyx and Cometriq that were developed by Alameda's Exelixis Inc. (NASDAQ: EXEL) and Novato-based Ultragenyx Pharmaceuticals Inc.'s (NASDAQ: RARE) rare disease drug Crysvita.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9009643771,"gmtCreate":1640661156910,"gmtModify":1676533532632,"author":{"id":"3582368268384555","authorId":"3582368268384555","name":"WaiLoon_","avatar":"https://static.tigerbbs.com/90a5a3740b140d3021b7bd9e72ad951b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582368268384555","authorIdStr":"3582368268384555"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009643771","repostId":1151631589,"repostType":4,"repost":{"id":"1151631589","kind":"news","pubTimestamp":1640659721,"share":"https://ttm.financial/m/news/1151631589?lang=&edition=fundamental","pubTime":"2021-12-28 10:48","market":"us","language":"en","title":"Gilead Sciences sued over royalty payments on key HIV drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1151631589","media":"THE BUSINESS JOURNALS","summary":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin ","content":"<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that seeks $125 million in damages.</p>\n<p>In the suit, filed Dec. 17 in San Mateo County Superior Court and moved last week to U.S. District Court in San Francisco, <a href=\"https://laohu8.com/S/RPRX\">Royalty Pharma plc</a> (NASDAQ: RPRX) claims Foster City-based Gilead (NASDAQ: GILD) failed to pay royalties on sales of drugs that use the antiviral therapy emtricitabine. That drug is sold as Emtriva but is now more often used as an ingredient in the HIV drugs Truvada, Atripla, Complera, Stribild, Eviplera, Genvoya, Odefsey, Descovy, Biktarvy and Symtuza.</p>\n<p>The lawsuit was filed by Royalty Pharma Collection Trust, a Wilmington, Delaware-based unit of the New York company, the largest buyer of drug royalties.</p>\n<p>With <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time cash payments to developers of drugs or technologies, companies such as Royalty Pharma provide capital in the present in exchange for a portion of a drug's sales in the future. The arrangement allows cash-strapped smaller companies or academic institutions, in particular, to monetize their work immediately instead of waiting for a drug to clear regulatory, sales or insurance reimbursement hurdles; for royalty buyers, it provides a potentially steady source of revenue for years to come.</p>\n<p>In the case of emtricitabine, Gilead and Royalty Pharma in 2005agreed to pay $525 millionto Emory University to eliminate Emtriva royalties due to the Atlanta school. Gilead covered 65% of the payment with Royalty Pharma picking up the remainder.</p>\n<p>Gilead also agreed to make a one-time payment of $15 million to Emory for amending its original license agreement with the university.</p>\n<p>But in a heavily redacted copy of the suit — 6-1/2 pages of the 12-page document, including the bulk of Royalty Pharma's claims, are blacked out — Royalty Pharma said Gilead has breached the agreement by failing to make royalty payouts as they were due.</p>\n<p>Royalty Pharma seeks recovery of what it claims is $125 million in damages, plus interest, attorneys' fees and costs and any other award from the court, and a declaration that Gilead must continue to pay royalties.</p>\n<p>In a statement to the San Francisco Business Times, Gilead said it is aware of the lawsuit and \"believes Royalty Pharma's claims are without merit and (Gilead) intends to vigorously defend itself against them.\"</p>\n<p>Emtriva was discovered by Emory researchers Dr.Dennis Liotta, Dr.Raymond Schinaziand Dr.Woo-Baeg Choiand licensed in 1996 to Triangle Pharmaceuticals by Emory. Triangle was bought by Gilead in January 2003 and Emtriva was approved by the Food and Drug Administration six months later.</p>\n<p>Emtricitabine, which acts with other drugs to slow the progress of the AIDS virus, has gone on to become a keystone in multiple HIV drugs developed and marketed by Gilead. That portfolio includes the once-daily, two-drug combo Truvada, which is approved as an HIV treatment but also was the first drug greenlighted to prevent HIV infection, and Symtuza, a drug approved in 2018 for Johnson &amp; Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit.</p>\n<p>HIV drug sales remain Gilead's top category, accounting for nearly $11.8 billion of the company's $19.8 billion in revenue in the nine months of this year ended Sept. 30.</p>\n<p>Gilead registered a profit of $5.8 billion through the first three quarters.</p>\n<p>Despite Gilead's successful expansion into hepatitis C, hepatitis B, cancer and cell therapy, those drugs either delivered a short pop in revenue or are too early in their product lifecycles to account for much revenue compared to the company's HIV franchise. The current exception is the Covid-19 drug remdesivir, branded as Veklury, that had 2021 sales through the third quarter of $4.2 billion.</p>\n<p>Royalty Pharma has had several agreements involving Bay Area drug makers, including royalties on the cancer drugs Cabometyx and Cometriq that were developed by Alameda's Exelixis Inc. (NASDAQ: EXEL) and Novato-based Ultragenyx Pharmaceuticals Inc.'s (NASDAQ: RARE) rare disease drug Crysvita.</p>","source":"lsy1633760424806","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences sued over royalty payments on key HIV drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences sued over royalty payments on key HIV drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 10:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo><strong>THE BUSINESS JOURNALS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that ...</p>\n\n<a href=\"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","GILD":"吉利德科学","BK4550":"红杉资本持仓","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","EXEL":"伊克力西斯","RPRX":"Royalty Pharma plc","BK4139":"生物科技"},"source_url":"https://www.bizjournals.com/sanfrancisco/news/2021/12/27/hiv-gilead-gild-royalty-pharma-emory-emtricitabine.html?ana=yahoo","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151631589","content_text":"HIV drug giant Gilead Sciences Inc. failed to pay royalties on sales of a drug that is the linchpin of the company's multibillion-dollar AIDS-fighting franchise, according to a recent lawsuit that seeks $125 million in damages.\nIn the suit, filed Dec. 17 in San Mateo County Superior Court and moved last week to U.S. District Court in San Francisco, Royalty Pharma plc (NASDAQ: RPRX) claims Foster City-based Gilead (NASDAQ: GILD) failed to pay royalties on sales of drugs that use the antiviral therapy emtricitabine. That drug is sold as Emtriva but is now more often used as an ingredient in the HIV drugs Truvada, Atripla, Complera, Stribild, Eviplera, Genvoya, Odefsey, Descovy, Biktarvy and Symtuza.\nThe lawsuit was filed by Royalty Pharma Collection Trust, a Wilmington, Delaware-based unit of the New York company, the largest buyer of drug royalties.\nWith one-time cash payments to developers of drugs or technologies, companies such as Royalty Pharma provide capital in the present in exchange for a portion of a drug's sales in the future. The arrangement allows cash-strapped smaller companies or academic institutions, in particular, to monetize their work immediately instead of waiting for a drug to clear regulatory, sales or insurance reimbursement hurdles; for royalty buyers, it provides a potentially steady source of revenue for years to come.\nIn the case of emtricitabine, Gilead and Royalty Pharma in 2005agreed to pay $525 millionto Emory University to eliminate Emtriva royalties due to the Atlanta school. Gilead covered 65% of the payment with Royalty Pharma picking up the remainder.\nGilead also agreed to make a one-time payment of $15 million to Emory for amending its original license agreement with the university.\nBut in a heavily redacted copy of the suit — 6-1/2 pages of the 12-page document, including the bulk of Royalty Pharma's claims, are blacked out — Royalty Pharma said Gilead has breached the agreement by failing to make royalty payouts as they were due.\nRoyalty Pharma seeks recovery of what it claims is $125 million in damages, plus interest, attorneys' fees and costs and any other award from the court, and a declaration that Gilead must continue to pay royalties.\nIn a statement to the San Francisco Business Times, Gilead said it is aware of the lawsuit and \"believes Royalty Pharma's claims are without merit and (Gilead) intends to vigorously defend itself against them.\"\nEmtriva was discovered by Emory researchers Dr.Dennis Liotta, Dr.Raymond Schinaziand Dr.Woo-Baeg Choiand licensed in 1996 to Triangle Pharmaceuticals by Emory. Triangle was bought by Gilead in January 2003 and Emtriva was approved by the Food and Drug Administration six months later.\nEmtricitabine, which acts with other drugs to slow the progress of the AIDS virus, has gone on to become a keystone in multiple HIV drugs developed and marketed by Gilead. That portfolio includes the once-daily, two-drug combo Truvada, which is approved as an HIV treatment but also was the first drug greenlighted to prevent HIV infection, and Symtuza, a drug approved in 2018 for Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit.\nHIV drug sales remain Gilead's top category, accounting for nearly $11.8 billion of the company's $19.8 billion in revenue in the nine months of this year ended Sept. 30.\nGilead registered a profit of $5.8 billion through the first three quarters.\nDespite Gilead's successful expansion into hepatitis C, hepatitis B, cancer and cell therapy, those drugs either delivered a short pop in revenue or are too early in their product lifecycles to account for much revenue compared to the company's HIV franchise. The current exception is the Covid-19 drug remdesivir, branded as Veklury, that had 2021 sales through the third quarter of $4.2 billion.\nRoyalty Pharma has had several agreements involving Bay Area drug makers, including royalties on the cancer drugs Cabometyx and Cometriq that were developed by Alameda's Exelixis Inc. (NASDAQ: EXEL) and Novato-based Ultragenyx Pharmaceuticals Inc.'s (NASDAQ: RARE) rare disease drug Crysvita.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":67,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}